AMERSCAN MDP KIT
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Aug 1982
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AMERSCAN MDP KIT is an injectable diagnostic radiopharmaceutical approved in 1982 by GE HealthCare. The product is used for nuclear medicine imaging, likely for cardiac or bone imaging based on its MDP (methylene diphosphonate) composition. It functions as a radiolabeled imaging agent to visualize tissue perfusion and metabolism.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), suggesting a defending-and-optimize strategy rather than growth investment.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on AMERSCAN MDP KIT offers limited growth trajectory but provides exposure to diagnostic product management and mature portfolio strategy within GE HealthCare. Career value lies in operational excellence, cost optimization, and market defense rather than innovation or launch dynamics.
Product ManagerCommercial Operations Manager
Worked on AMERSCAN MDP KIT at GE HealthCare? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.